Skip to main content
. 2024 Apr 5;11(1):e001954. doi: 10.1136/bmjresp-2023-001954

Table 4.

General characteristics of 6902 patients with COPD in the COPD primary healthcare cohort study

Characteristics Overall
(n=6902)
Men
(n=5534)
Women
(n=1368)
Age, year 70.30±9.801 70.26±9.508 70.48±10.907
Age groups, n (%)
 18–29 13 (0.2) 8 (0.1) 5 (0.4)
 30–39 17 (0.2) 11 (0.2) 6 (0.4)
 40–49 94 (1.4) 68 (1.2) 26 (1.9)
 50–59 866 (12.5) 670 (12.1) 196 (14.3)
 60–69 2029 (29.4) 1686 (30.5) 343 (25.1)
 70~ 3883 (56.3) 3091 (55.9) 792 (57.9)
Smoking exposure, pack-years, n (%)
 0 2174 (31.5) 963 (17.4) 1211 (88.5)
 1–14.9 744 (10.8) 689 (12.5) 55 (4.0)
 15–29.9 1103 (26.0) 1055 (19.1) 48 (3.5)
 ≥30 2881 (41.7) 2827 (51.1) 54 (3.9)
Household biofuel exposure, n (%)
 Yes 1774 (25.7) 1299 (23.5) 475 (34.7)
 No 5128 (74.3) 4235 (76.5) 893 (65.3)
Family history of respiratory diseases, n (%)
 Yes 1713 (24.8) 1261 (22.8) 452 (33.0)
 No 5189 (75.2) 4273 (77.2) 916 (77.0)
mMRC, n (%)
 0–1 2379 (34.5) 1905 (34.4) 474 (34.6)
 ≥2 4523 (65.5) 3629 (65.6) 894 (65.4)
CAT, n (%)
 <10 980 (14.2) 770 (13.9) 210 (15.4)
 ≥10 5922 (85.8) 4764 (86.1) 1158 (84.6)
Therapy, n (%)
 SABA or SAMA 723 (10.5) 584 (10.6) 139 (10.2)
 LABA or LAMA 2029 (29.4) 1636 (29.6) 393 (28.7)
 LAMA+LABA or ICS+LABA 2084 (30.2) 1692 (30.6) 392 (28.7)
 ICS+LAMA+LABA 704 (10.2) 604 (10.9) 100 (7.3)
 ICS 487 (7.1) 405 (7.3) 82 (6.0)
 Non-inhalation therpy 875 (12.7) 613 (11.1) 262 (19.2)

Notes: Values are mean (SD) or n (%).

Collected during November 2021 and March 2023.

CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids; LABA, long-acting β-agonists; LAMA, long-acting muscarinic antagonist; mMRC, the modified Medical Research Council Dyspnoea Scale; SABA, short-acting β-agonists; SAMA, short-acting muscarinic antagonist.